Company Epigenomics AG Deutsche Boerse AG
Equities
DE000A1K0516
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Business Summary
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
In Vitro Diagnostic - Products
95.9
%
| 0 | 7.5 % | 0 | 95.9 % | 0.00% |
Licensing
4.1
%
| 0 | 0.4 % | 0 | 4.1 % | -9.09% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
North America
54.2
%
| 0 | 4.8 % | 0 | 54.2 % | -11.45% |
Europe
38.6
%
| 0 | 3.0 % | 0 | 38.6 % | -1.06% |
Asia
7.2
%
| 6 | 92.2 % | 0 | 7.2 % | -99.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frederic Hilke
IRC | Investor Relations Contact | - | - |
Annett Dietrich
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Helge Lubenow
CHM | Chairman | 56 | 24/05/16 |
Jochen Hummel
BRD | Director/Board Member | 54 | 02-04 |
Alexander Link
BRD | Director/Board Member | 53 | 31/05/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 875,150 | 584,339 ( 66.77 %) | 0 | 66.77 % |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-27.67% | 9.87B | |
+34.87% | 3.07B | |
-17.30% | 2.73B | |
-11.15% | 2.24B | |
-22.32% | 1.63B | |
+23.58% | 771M | |
-1.31% | 760M | |
-28.57% | 516M | |
+5.37% | 310M |
- Stock Market
- Equities
- ECX Stock
- Stock
- Company Epigenomics AG